Trial Profile
A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms NILOdeepR
- Sponsors Novartis; Novartis Pharmaceuticals
- 07 Apr 2021 Status changed from active, no longer recruiting to completed.
- 07 Sep 2020 Planned End Date changed from 22 Feb 2021 to 20 Mar 2021.
- 06 Jan 2020 Status changed from recruiting to active, no longer recruiting.